Sotrovimab – Emergency use authorization revision
April 5, 2022 - The FDA announced that GlaxoSmithKline’s sotrovimab is no longer authorized to treat COVID-19 in any U.S. region due to increases in the proportion of COVID-19 cases caused by the Omicron BA.2 sub-variant.
Download PDF
